Pharmaceuticals
NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
MILAN, Dec. 5, 2024 /PRNewswire/ -- NTC, an international R&D focused pharmaceutical company headquartered inItaly, presents positive results from Phase II MIRAKLE study, a multicentre, randomized, blinded-assessor, phase II non-inferiority study evaluatingthe efficacy and tolerability of NTC014 ...
2024-12-05 19:00
2621
CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial
MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). Key...
2024-12-05 11:59
2678
LBB Specialties and Clariant Partner to Distribute High-Quality Pharmaceutical Grade PEGs for Ophthalmic Applications
NORWALK, Conn., Dec. 5, 2024 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, announced a strategic partnership with Clariant, a global leader in specialty chemical manufacturing. Through this collaboration, LBB Specialties will ...
2024-12-05 04:02
2012
Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved mapping and dual energy ablation catheter
AUSTIN, Texas, Dec. 4, 2024 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to use an all-in-one high-density mapping and dual energy ablation catheter for the treatment of persistent atria...
2024-12-04 10:07
2645
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
* Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission. * In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and ...
2024-12-04 09:10
3001
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoi...
2024-12-04 08:00
3634
AC Health makes critical HIV care more accessible to Filipinos with USAID support
MANILA, Philippines, Dec. 3, 2024 /PRNewswire/ -- Ayala Healthcare Holdings, Inc. (AC Health), in partnership with the U.S. Agency for International Development (USAID), is leading the private sector's efforts to fight the HIV epidemic inthe Philippines by improving access to stigma-free care and...
2024-12-03 16:11
5791
Pfizer Receives Authorization from Health Authority for Its 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
* In Hong Kong, the 20-valent Pneumococcal Conjugate Vaccine (PCV20) that offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine – helping to fight against 20 serotypesleading to most of the invasive pneumococcal diseases and pneumonia[i],[ii] – is now approved fo...
2024-12-03 15:08
2518
Fosun's Rural Doctors Program Recognized in UNGC's "20 Cases of Private Sector's Sustainable Development in China for 20 Years" Report
HONG KONG, Dec. 3, 2024 /PRNewswire/ -- This year marks the 20th anniversary of the United Nations Global Compact ("UNGC")'s introduction of Environmental, Social, and Governance (ESG) concept and principles. On29 November 2024, the UNGC held a launch event for the "20 Cases of Private Sector's S...
2024-12-03 11:47
2778
European Wellness Biomedical Group, Headed by Prof. Mike Chan, Releases New Study on Bioregenerative Blueprint for Athletic Longevity
KOTA KINABALU, Malaysia, Dec. 2, 2024 /PRNewswire/ -- European Wellness Biomedical Group (EWBG), a global leader in regenerative medicine, has unveiled a groundbreaking study led by renowned expert Prof.Mike Chan on the physiological challenges aging athletes face. The analysis explores how age ...
2024-12-02 16:30
3978
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Hong Kong
SHANGHAI, Dec. 2, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Gover...
2024-12-02 07:40
2719
CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China
* CBC Group and Mubadala acquire UCB's mature neurology and allergy business inChina for US$680 million. * New company is named NeuroGen Pharma, led by an experienced management team with a strong track record in the biopharma industry. * Strategic acquisition under CBC's buyout strategy exp...
2024-11-30 09:00
6543
Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific...
2024-11-28 21:30
4586
First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients
MELBOURNE, Australia, Nov. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma) today announce that a first patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron ...
2024-11-28 17:22
3064
New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List
ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the new indication...
2024-11-28 16:59
3625
Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List
SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has been included in the...
2024-11-28 13:43
2923
Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country
SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hema...
2024-11-28 13:04
3167
Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List
SAN FRANCISCO and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-11-28 12:07
4383
Everest Medicines to Hold Investor Calls on Data Results from EVER001 Phase 1b/2a Clinical Study in Primary Membranous Nephropathy
SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will hold investor calls on t...
2024-11-27 19:08
3688
Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC
CHENGDU, China, Nov. 27, 2024 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization inChina from National Medical Products Administration (NMPA) for the first domestically developed trophoblast cell-surface an...
2024-11-27 14:34
2770
Week's Top Stories
Most Reposted
Global virtual travel card program launched by Visa and Trip.com to make travel payments simpler and more seamless in Asia Pacific
[Picked up by 330 media titles]
2026-03-11 11:08PDG Targets USD 5 Billion Debt Raise
[Picked up by 295 media titles]
2026-03-11 10:00The Mastercard Collection: Savor the Extraordinary with Mastercard's Asia Gourmet Circle Program
[Picked up by 295 media titles]
2026-03-12 09:00TelkomMetra Streamlines Business Portfolio, AdMedika Group Poised to Enter a New Growth Phase on Regional Level Under Fullerton Health
[Picked up by 295 media titles]
2026-03-09 21:36
Progress Software Highlights Load Balancing as a Strategic Imperative for APAC Digital Infrastructure Resilience
[Picked up by 290 media titles]
2026-03-10 09:00
Most Read
Say Goodbye to Expensive Subscriptions, Hello to 4K: the All-in-One XbotGo Falcon AI Sports Camera Now Available for Global Public Sale
2026-03-06 23:20
7603
A French Electronic Storm is Brewing Over Victoria Harbour: DJ Snake to Headline French May Arts Festival 2026
2026-03-06 23:22
7120
CARsgen Therapeutics Announces 2025 Annual Results
2026-03-06 20:03
6691
